Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Liabilities and Shareholders Equity: 2018-2025

Historic Liabilities and Shareholders Equity for Whitehawk Therapeutics (WHWK) over the last 8 years, with Sep 2025 value amounting to $167.0 million.

  • Whitehawk Therapeutics' Liabilities and Shareholders Equity rose 94.89% to $167.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $652.2 million, marking a year-over-year increase of 51.38%. This contributed to the annual value of $70.3 million for FY2024, which is 46.90% down from last year.
  • Whitehawk Therapeutics' Liabilities and Shareholders Equity amounted to $167.0 million in Q3 2025, which was down 7.63% from $180.8 million recorded in Q2 2025.
  • In the past 5 years, Whitehawk Therapeutics' Liabilities and Shareholders Equity registered a high of $234.0 million during Q1 2025, and its lowest value of $37.4 million during Q2 2021.
  • Over the past 3 years, Whitehawk Therapeutics' median Liabilities and Shareholders Equity value was $139.7 million (recorded in 2023), while the average stood at $140.4 million.
  • In the last 5 years, Whitehawk Therapeutics' Liabilities and Shareholders Equity skyrocketed by 738.83% in 2021 and then crashed by 46.90% in 2024.
  • Quarterly analysis of 5 years shows Whitehawk Therapeutics' Liabilities and Shareholders Equity stood at $157.9 million in 2021, then rose by 16.67% to $184.2 million in 2022, then decreased by 28.12% to $132.4 million in 2023, then tumbled by 46.90% to $70.3 million in 2024, then skyrocketed by 94.89% to $167.0 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $167.0 million for Q3 2025, versus $180.8 million for Q2 2025 and $234.0 million for Q1 2025.